Glaucoma medications in pregnancy

• Main Author: M Reza Razeghinejad
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2018-01-01
• Series: Oman Journal of Ophthalmology
• Subjects: Alpha-2 agonists; beta-blockers; carbonic anhydrase inhibitors; glaucoma; glaucoma medications; pregnancy; prostaglandins
• Online Access: http://www.ojoonline.org/article.asp?issn=0974-620X;year=2018;volume=11;issue=3;spage=195;epage=199;aulast=Razeghinejad

Glaucoma is a chronic, progressive disease of the optic nerve which is relatively uncommon in childbearing age; however, its management is a real challenge. Although the intraocular pressure decreases in pregnancy, many glaucoma patients continue to require treatment. In addition to the side effects, antiglaucoma medications on the mother, the possible side effects of drugs on the fetus must be taken into account. The only antiglaucoma medication categorized in Category B is brimonidine, and all others are in Category C. Most evidence on glaucoma medications in pregnancy comes from single case reports or animal studies with the limitations that these impose. Theoretically, glaucoma medications may damage the fetus; however, they may not have substantial clinical significance with routine dosages and no topical antiglaucoma agents have strong evidence of safety to the fetus based on the human studies. When discussing possible options for glaucoma management with the pregnant patient, it is important to emphasize the lack of definitive studies and the patient may be involved in the therapeutic decision-making process.